Civica

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.

Out of Control: U.S. Employers Spend $245B a Year on Diabetes as Diagnosis Rates Rise, New Nomi Health Data Shows

Retrieved on: 
Tuesday, March 14, 2023

Diabetes costs U.S. employers approximately $245 billion a year — more than double what the entire American automotive industry is worth, according to new data announced today by Nomi Health .

Key Points: 
  • Diabetes costs U.S. employers approximately $245 billion a year — more than double what the entire American automotive industry is worth, according to new data announced today by Nomi Health .
  • As part of the Nomi Health Trends in Spend Tracker — a series using claims analysis data to call attention and action to key shifts in healthcare costs — Nomi Health analyzed nearly half a million employer health insurance claims to reveal changes in employer spend on diabetes.
  • We must turn these spend insights into meaningful action,” Nomi Health Co-founder and CEO Mark Newman said.
  • Previous Nomi Health Trends in Spend Trackers explored pediatric mental health utilization and the costs of long COVID , which outpaced diabetes in 2022 employer health care costs.

Nomi Health Launches Charitable Foundation to Expand Access to Affordable, High-Quality Healthcare

Retrieved on: 
Thursday, February 23, 2023

Nomi Health , a direct healthcare company, has announced the creation of the Nomi Health Charitable Foundation to advance the company’s efforts to expand access to high-quality affordable healthcare across the United States.

Key Points: 
  • Nomi Health , a direct healthcare company, has announced the creation of the Nomi Health Charitable Foundation to advance the company’s efforts to expand access to high-quality affordable healthcare across the United States.
  • “Our mission at Nomi Health is to rewire the U.S. healthcare system to run at half the cost while increasing access for all.
  • That’s why we’re launching the Nomi Health Charitable Foundation to formalize our years-long commitment to take on the deeply rooted inequalities in our broken healthcare system and to uplift those who have been left behind.”
    Through philanthropic investments and partnerships, the Nomi Health Charitable Foundation will focus on four key areas of impact:
    Healthcare Equity: Nomi Health focuses on addressing health disparities by increasing access to affordable, high-quality care – including mental healthcare.
  • The Nomi Health Charitable Foundation is launching a new signature program – The Frontline Futures Program – to support students and young professionals pursuing careers in healthcare.

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

Retrieved on: 
Tuesday, January 31, 2023

Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.
  • To ensure redundancy of supply, Ypsomed will provide injector dosing pens from their two manufacturing facilities in Switzerland and Germany.
  • “As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica.
  • Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.

AmerisourceBergen Kicks Off Strategic Relationship with Civica

Retrieved on: 
Monday, January 23, 2023

Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.

Key Points: 
  • Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.
  • Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely.
  • View the full release here: https://www.businesswire.com/news/home/20230123005078/en/
    “We are thrilled to have AmerisourceBergen as our like-minded distribution and supply chain partner as we continue to grow our hospital network,” said Ned McCoy, President and CEO of Civica.
  • More than 1,500 pharmaceutical manufacturers and tens of thousands of healthcare providers rely on AmerisourceBergen every day to deliver critical medicines and treatments.

Emerging Life Sciences Market Shapes the Region

Retrieved on: 
Monday, November 21, 2022

RICHMOND, Va., Nov. 21, 2022 /PRNewswire/ -- In a panel focused on current advanced manufacturing and life science developments hosted by BISNOW, DPR Construction's Raj Vora offered his thoughts on Richmond's rich business climate. Vora shared his insights on how Richmond compared to the larger biotechnology hubs along Maryland's I-270 Corridor and North Carolina's Raleigh-Durham region.

Key Points: 
  • Vora shared his insights on how Richmond compared to the larger biotechnology hubs along Maryland's I-270 Corridor and North Carolina's Raleigh-Durham region.
  • "The educated workforce and quality of life in the region, amplified by Richmond's proximity to research facilities, has attracted newcomers and life sciences startups," said Vora.
  • The key takeaway should be cautious optimism with a positive outlook on the life sciences industry's ability to take hold in Richmond."
  • DPR Construction is a forward-thinking, self-performing general contractor and construction manager specializing in technically complex and sustainable projects for the advanced technology, life sciences, healthcare, higher education and commercial markets.

Richmond-Petersburg Region is a Winner of the National Build Back Better Regional Challenge

Retrieved on: 
Friday, September 2, 2022

The coalition is one of only 21 coalitions to receive funding from the Build Back Better Regional Challenge.

Key Points: 
  • The coalition is one of only 21 coalitions to receive funding from the Build Back Better Regional Challenge.
  • Coalition members will leverage the Build Back Better Regional Challenge funding for six construction and programmatic projects.
  • Funding from the Build Back Better Regional Challenge will help the region create a secure supply of essential medicines for the U.S., re-shore manufacturing by tapping into new technologies, and reduce the cost and increase access to quality medicines for Americans.
  • "We thank the General Assembly and governor, GO Virginia and VEDP for strong and growing support for this emerging regional cluster.

Lumicera Health Services Now Offering The First Landmark Drug From CivicaScript™

Retrieved on: 
Thursday, August 11, 2022

Lumicera Health Services, a specialty pharmacy wholly owned by Navitus Health Solutions, announced today that it will be offering abiraterone acetate 250 mg tablets the first landmark generic drug made available by CivicaScript.

Key Points: 
  • Lumicera Health Services, a specialty pharmacy wholly owned by Navitus Health Solutions, announced today that it will be offering abiraterone acetate 250 mg tablets the first landmark generic drug made available by CivicaScript.
  • The partnership between Lumicera and CivicaScript provides an opportunity to uniquely benefit payors and patients by furthering the shared commitment to transparency and drug affordability.
  • This drug launch comes on the heels of Navitus Health Solutions announcing it has joined CivicaScript as a founding member.
  • Navitus Health Solutions, owned by SSM Health and Costco Wholesale Corporation, is a disruptive industry alternative to traditional pharmacy benefit manager (PBM) models.

ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development

Retrieved on: 
Tuesday, August 9, 2022

WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M. as chief financial officer (CFO) and head of business development. Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.

Key Points: 
  • WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M.
  • as chief financial officer (CFO) and head of business development.
  • Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.
  • "It is exciting to join ImmPACT Bio at its current stage of successful product development and help scale-up and deliver the pipeline of next-generation CAR T-cell therapies," said Mr. Lamba.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

Retrieved on: 
Wednesday, August 3, 2022

Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.

Key Points: 
  • Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.
  • Abiraterone was chosen by CivicaScriptmembers as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
  • This is a proud day for CivicaScript as we advance our mission to make generic medicines affordable and available to everyone, said CivicaScript President Gina Guinasso.
  • CivicaScript then works with like-minded payors, PBMs and pharmacies across the country who pass along the cost savings to their customers.